OCUGEN, INC. Operating Lease, Payments
OCUGEN, INC. (OCGN) reported Operating Lease, Payments of $1.17 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-04.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:OperatingLeasePayments · last filed 2026-03-04
- OCUGEN, INC. operating lease, payments for the quarter ending 2019-03-31 was $459.00K.
- OCUGEN, INC. operating lease, payments for fiscal 2025 was $1.17M, a 43.49% increase from fiscal 2024.
- OCUGEN, INC. operating lease, payments for fiscal 2024 was $814.00K.
| Period end | Operating Lease, Payments 3 month | Operating Lease, Payments 12 month |
|---|---|---|
| 2025-12-31 | $1.17M 10-K · filed 2026-03-04 | |
| 2024-12-31 | $814.00K 10-K · filed 2026-03-04 | |
| 2019-03-31 | $459.00K 10-Q · filed 2019-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |